Jax DiEugenio

Neoadjuvant dostarlimab led to an 82% clinical complete response and a 92% 2-year RFS rate, supporting nonoperative management in early-stage dMMR tumors.

FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.

The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

KN026 plus chemotherapy significantly improves PFS in second-line and later HER2-positive advanced gastric/GEJ cancer.

Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer.

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.

Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.

Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.